Alzheimer's disease in France: too many patients exposed to drug interactions involving cholinesterase inhibitors.
A study based on data from the French national health insurance system, for the period 2003-2011, has shown that patients with Alzheimer's disease receiving a cholinesterase inhibitor were exposed to another drug that reduces the heart rate in about 44% of cases, a neuroleptic in 33% of cases, and an antimuscarinic for urinary problems in 8% of cases. Drugs for Alzheimer's disease expose patients to dangerous drug-drug interactions.